Claims for Patent: 8,809,394

Summary for Patent: 8,809,394

Title:	Tranexamic acid formulations
Abstract:	Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Inventor(s):	Moore; Keith A. (Loveland, OH), Heasley; Ralph A. (Webster Grove, MO), Greiwe; Jeffrey S. (Ft. Thomas, KY), Facemire; John W. (Douglasville, GA), Modest; Jason D. (Minneapolis, MN)
Assignee:	Ferring B.V. (Hoofddorp, NL)
Application Number:	13/544,685
Patent Claims:	1. A tranexamic acid tablet formulation comprising: tranexamic acid or a pharmaceutically acceptable salt thereof; and a modified release material; wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 50% to about 95% by weight of the formulation; wherein the modified release material is present in an amount from about 5% to about 50% by weight of the formulation; and wherein said formulation provides an in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof, when measured by a USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37.+-.0.5.degree. C., of less than about 70% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 45 minutes and not less than about 50% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 90 minutes. 2. The tranexamic acid tablet formulation of claim 1, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 3. The tranexamic acid tablet formulation of claim 1, wherein formulation provides a dose of about 650 mg of tranexamic acid per tablet. 4. The tranexamic acid tablet formulation of claim 3, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 5. The tranexamic acid tablet formulation of claim 1, wherein the modified release material comprises hydroxypropylmethylcellulose. 6. The tranexamic acid tablet formulation of claim 5, wherein formulation provides a dose of about 650 mg of tranexamic acid per tablet. 7. The tranexamic acid tablet formulation of claim 6, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 8. The tranexamic acid tablet formulation of claim 1, wherein the formulation is in the form of a matrix tablet which comprises a drug mixed together with a granulated modified release material. 9. The tranexamic acid tablet formulation of claim 8, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet. 10. The tranexamic acid tablet formulation of claim 9, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 11. The tranexamic acid tablet formulation of claim 1, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation. 12. The tranexamic acid tablet formulation of claim 1, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 80% by weight of the formulation. 13. The tranexamic acid tablet formulation of claim 1, wherein the modified release material is present in an amount from about 10% to about 35% by weight of the formulation. 14. The tranexamic acid tablet formulation of claim 1, wherein: the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation; the formulation is in the form of a matrix tablet which comprises a granulated drug mixed together with the modified release material and the formulation provides a dose of about 650 mg of tranexamic acid per tablet. 15. The tranexamic acid tablet formulation of claim 14, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 16. The tranexamic acid tablet formulation of claim 14, wherein the modified release material comprises hydroxypropylmethylcellulose. 17. The tranexamic acid tablet formulation of claim 16, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 18. An oral dosage form comprising a tranexamic acid tablet formulation according to claim 1 coated with a film. 19. The oral dosage form of claim 18, wherein the film comprises a film-forming agent present in an amount in the range from about 2% tablet weight to about 4% tablet weight. 20. The oral dosage form of claim 18, wherein the film comprises a film-forming agent forming agent that comprises a (diethylaminoethyl)methacrylate/methyl-butyl-methacrylate copolymer. 21. The oral dosage form of claim 20, wherein the film forming agent comprises Eudragit E. 22. The oral dosage form of claim 18, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 23. The oral dosage form of claim 18, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet. 24. The oral dosage form of claim 23, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 25. The oral dosage form of claim 18, wherein the modified release material comprises hydroxypropylmethylcellulose. 26. The oral dosage form of claim 25, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet. 27. The oral dosage form of claim 26, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 28. The oral dosage form of claim 18, wherein the formulation is in the form of a matrix tablet which comprises a drug mixed together with a granulated modified release material. 29. The oral dosage form of claim 28, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet. 30. The oral dosage form of claim 29, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 31. The oral dosage form of claim 18, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation. 32. The oral dosage form of claim 18, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 80% by weight of the formulation. 33. The oral dosage form of claim 18, wherein the modified release material is present in an amount from about 10% to about 35% by weight of the formulation. 34. The oral dosage form of claim 18, wherein: the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation; the formulation is in the form of a matrix tablet which comprises a granulated drug mixed together with the modified release material and the formulation provides a dose of about 650 mg of tranexamic acid per tablet. 35. The oral dosage form of claim 34, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 36. The oral dosage form of claim 34, wherein the modified release material comprises hydroxypropylmethylcellulose. 37. The oral dosage form of claim 36, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid. 38. A method of treating menorrhagia comprising administering to a patient in need of such treatment at least one tablet of the tranexamic acid formulation of claim 1, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet. 39. A method of treating menorrhagia comprising administering to a patient in need of such treatment at least one tablet of the tranexamic acid formulation of claim 18, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet. 40. The method of claim 38 wherein: the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation; and the modified release material is present in an amount from about 10% to about 35% by weight of the formulation. 41. The method of claim 39, wherein: the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation; and the modified release material is present in an amount from about 10% to about 35% by weight of the formulation.